Press Releases
Filter By Year
September
-
September 19, 2023
CHMP Adopts Positive Opinion to Extend the Use of Veklury® (Remdesivir) to Treat COVID-19 in People With Hepatic Impairment -
September 18, 2023
Kite’s Car T-cell Therapy Yescarta® Demonstrates High Response Rate and Durable Remission in ALYCANTE Study as Initial Treatment for Transplant Ineligible Patients With Relapsed/Refractory Large B-cell Lymphoma -
September 10, 2023
Gilead’s Phase 2 EVOKE-02 Study of Trodelvy® (sacituzumab govitecan-hziy) in Combination With KEYTRUDA® (pembrolizumab) Demonstrates Promising Clinical Activity in First-Line Metastatic Non-Small Cell Lung Cancer -
September 07, 2023
Gilead Prices $2 Billion of Senior Unsecured Notes
August
-
August 24, 2023
FDA Approves Veklury® (Remdesivir) to Treat COVID-19 in People With Mild to Severe Hepatic Impairment With no Dose Adjustment -
August 23, 2023
Gilead Sciences to Present at Upcoming Investor Conferences -
August 21, 2023
Gilead Announces Partial Clinical Hold for Magrolimab Studies in AML -
August 18, 2023
Gilead Sciences and Meharry Medical College Highlight Five-Year Impact of Gilead COMPASS Initiative® on HIV in the Southern United States -
August 15, 2023
Gilead and Tentarix to Discover and Develop Novel Therapies to Address Unmet Medical Needs Across Cancer and Inflammation -
August 03, 2023
Gilead Sciences Announces Second Quarter 2023 Financial Results
July
-
July 27, 2023
European Commission Approves Gilead’s Trodelvy® For Pre-Treated HR+/HER2- Metastatic Breast Cancer -
July 24, 2023
Twice-Yearly Lenacapavir Demonstrates Sustained Impact on Health-Related Quality of Life in People With HIV -
July 23, 2023
New Biktarvy® Data Presented at IAS 2023 Further Demonstrate Safety and Efficacy Profile in a Broad Range of People and Communities Affected by the Global HIV Epidemic -
July 23, 2023
Gilead Sciences Announces Its Largest Commitment to Health Equity for Australian and Canadian Indigenous Communities -
July 21, 2023
Gilead To Discontinue Phase 3 ENHANCE Study of Magrolimab Plus Azacitidine in Higher-Risk MDS -
July 20, 2023
Gilead Announces $8 Million in Grant Funding for Viral Hepatitis Relink Program in the U.S. -
July 19, 2023
Gilead Showcases Latest HIV Pipeline Progress and the Impact of Global Collaboration on Health Equity Efforts at IAS 2023 -
July 14, 2023
Gilead Sciences to Release Second Quarter 2023 Financial Results on Thursday, August 3, 2023 -
July 14, 2023
FDA Approves Veklury® (Remdesivir) for COVID-19 Treatment in Patients With Severe Renal Impairment, Including Those on Dialysis -
July 13, 2023
Gilead Partners with CHAI and Penta to Improve Treatment and Adherence Rates Among Children with HIV in Low and Middle Income Countries
June
-
June 23, 2023
Gilead Receives CHMP Positive Opinion for Trodelvy® in Pre-Treated HR+/HER2- Metastatic Breast Cancer -
June 23, 2023
Hepcludex® (Bulevirtide) Demonstrates Sustained Efficacy and Safety Profile in People With Chronic Hepatitis Delta Virus at 96 Weeks -
June 22, 2023
Kite Announces Completion of Marketing Authorization Transfer for Yescarta® CAR T-cell Therapy in Japan -
June 14, 2023
Gilead to Present Latest Liver Disease Research at the European Association for the Study of the Liver (EASL) Congress 2023 -
June 06, 2023
Kite’s Tecartus® CAR T-cell Therapy Demonstrates 78% Complete Response Rate and 90% Overall Response Rate in Largest Real-World Evidence Analysis for Relapsed/Refractory Mantle Cell Lymphoma -
June 05, 2023
Trodelvy® Continues to Show Durable Overall Survival Advantage in Pre-Treated HR+/HER2- Metastatic Breast Cancer -
June 05, 2023
Kite’s Yescarta® CAR T-cell Therapy Demonstrates Significantly Longer Overall Survival Versus Standard of Care as Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma -
June 03, 2023
Gilead and Arcus Announce Anti-TIGIT Domvanalimab Continues to Demonstrate Consistent Improvement in Progression-Free Survival in Non-Small Cell Lung Cancer Study -
June 01, 2023
Gilead and Kite Oncology Demonstrate Growing Hematology Pipeline and Strength of Leading Cell Therapy Portfolio at EHA
May
-
May 26, 2023
CHMP Adopts Positive Opinion to Extend the Use of Veklury® (Remdesivir) to Treat COVID-19 in People With Severe Renal Impairment, Including Those on Dialysis -
May 25, 2023
Gilead Sciences to Present at Upcoming Investor Conference -
May 17, 2023
Gilead and Kite Oncology to Showcase Advances Across the Pipeline Aiming to Address Unmet Needs in Cancer Care at ASCO 2023 -
May 16, 2023
Gilead Appoints Cindy Perettie Executive Vice President of Kite -
May 15, 2023
Gilead Sciences and Arcus Biosciences Expand Partnership to Include Research Programs in Inflammation -
May 09, 2023
Gilead Strengthens Early Pipeline in Oncology and Inflammation Through the Acquisition of XinThera -
May 04, 2023
CHMP Adopts Positive Opinion Recommending Hepcludex® (Bulevirtide) for Full Marketing Authorization for the Treatment of Hepatitis Delta Virus (HDV)
April
-
April 27, 2023
Gilead Sciences Announces First Quarter 2023 Financial Results -
April 16, 2023
Veklury® (Remdesivir) Efficacy and Safety Profile Further Demonstrated in Vulnerable Patient Populations -
April 13, 2023
Gilead Sciences to Release First Quarter 2023 Financial Results on Thursday, April 27, 2023
March
-
March 22, 2023
Gilead Sciences Announces $3 Million in Grant Funding to Eight Organizations Addressing HIV Disparities in Rural U.S. Communities -
March 21, 2023
Kite’s Yescarta® CAR T-cell Therapy Demonstrates a Statistically Significant Improvement in Overall Survival for Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma -
March 20, 2023
Gilead Exercises Option to License Nurix’s IRAK4 Targeted Protein Degrader Development Candidate, NX-0479
February
-
February 22, 2023
Gilead Presents Positive Proof-of-Concept Data for Investigational Combination Regimen of Lenacapavir with Broadly Neutralizing Antibodies as a Potential Twice-Yearly Approach for the Treatment of HIV -
February 22, 2023
Kite Completes Acquisition of Tmunity -
February 21, 2023
Veklury® (Remdesivir) Reduced Risk of Mortality in Hospitalized COVID-19 Patients Across all Variant Time Periods in a Real World Study of More than 500,000 Hospitalized Patients -
February 21, 2023
Gilead Presents New Data From HIV Cure Research Program and Collaborations Exploring Novel Investigational Combinations and Strategies -
February 17, 2023
Trodelvy® Demonstrates Positive Efficacy Treating Both Platinum-Ineligible and Rapidly Progressing, Post-Platinum Metastatic Urothelial Cancer -
February 14, 2023
Gilead Demonstrates Transformative Potential Impact Of Antiviral Innovation at CROI 2023 -
February 09, 2023
Kite’s Tecartus® CAR T-Cell Therapy Demonstrates Overall Survival Benefit in Three-Year Follow-up of Pivotal ZUMA-3 Trial in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia -
February 03, 2023
U.S. FDA Approves Trodelvy® in Pre-treated HR+/HER2- Metastatic Breast Cancer -
February 02, 2023
Gilead Sciences Announces 2.7 Percent Increase in First Quarter 2023 Dividend -
February 02, 2023
Gilead Sciences Announces Fourth Quarter and Full Year 2022 Financial Results -
February 01, 2023
Gilead Awards $7.6 Million in Grants to Advance Health Equity in Breast Cancer
January
-
January 30, 2023
Kite and Arcellx Close Agreement to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma -
January 27, 2023
Gilead Sciences to Present at Upcoming Investor Conferences -
January 19, 2023
Gilead Sciences to Release Fourth Quarter & Full Year 2022 Financial Results on Thursday, February 2, 2023 -
January 03, 2023
European Medicines Agency Validates Marketing Authorization Application For Trodelvy® (sacituzumab govitecan-hziy) For Pre-treated HR+/HER2- Metastatic Breast Cancer -
January 03, 2023
Gilead and EVOQ Therapeutics Announce Collaboration to Advance Immunotherapies
Filter By Year